F
Fabrice Barlesi
Researcher at Aix-Marseille University
Publications - 666
Citations - 36214
Fabrice Barlesi is an academic researcher from Aix-Marseille University. The author has contributed to research in topics: Lung cancer & Medicine. The author has an hindex of 64, co-authored 582 publications receiving 25403 citations. Previous affiliations of Fabrice Barlesi include Institut Gustave Roussy & Nord University.
Papers
More filters
Proceedings ArticleDOI
Abstract CT209: A phase I study with the oral pan-CDK inhibitor BAY 1000394 in patients with advanced stage small cell lung or ovarian cancer
Rastilav Bahleda,Fabrice Barlesi,Christine Audebert,Maurice Pérol,Isabelle Ray-Coquard,Dirk Strumberg,Beate Schultheis,Ramaswamy Govindan,Grace K. Dy,Gérard Zalcman,Annette O. Walter,Martin Kornacker,Matthias Ocker,Jean-Charles Soria +13 more
TL;DR: The continuous oral treatment with the pan-CDK inhibitor BAY 1000394 is feasible and showed signs of efficacy and pharmacodynamic activity at 5 mg bid on a 3-days on/4-days off treatment schedule in a non-biomarker selected expansion population of phase I patients with advanced stage SCLC or ovarian cancer.
Journal ArticleDOI
Sustained cancer clinical trial activity in a French hospital during the first wave of the COVID-19 pandemic.
Arnaud Bayle,Arnaud Bayle,Arnaud Bayle,Capucine Baldini,Patricia Martin-Romano,Jean-Marie Michot,Stéphane Champiat,Rastilav Bahleda,Anas Gazzah,Aurélien Marabelle,Loic Verlingue,Arthur Geraud,Daphné Morel,Stefan Michiels,Antoine Hollebecque,Laurence Albiges,Benjamin Besse,Jean-Charles Soria,Christophe Massard,Fabrice Barlesi,Sophie Postel-Vinay,Sophie Postel-Vinay +21 more
Journal ArticleDOI
Qualité de la prise en charge de la douleur des patients atteints de cancer bronchique en médecine générale
TL;DR: In this article, the authors evaluate the role of generalistes and their connaissance des recommandations du traitement de la douleur des patients atteints d'un cancer bronchique primitif (CBP).
Journal ArticleDOI
Efficacy of pemetrexed as second-line therapy in advanced NSCLC after either treatment-free interval or maintenance therapy with gemcitabine or erlotinib in IFCT-GFPC 05-02 phase III study.
O. Bylicki,Celine Ferlay,Christos Chouaid,Armelle Lavolle,Fabrice Barlesi,Radj Gervais,Virginie Westeel,Jacky Crequit,Romain Corre,Alain Vergnenegre,Gérard Zalcman,Isabelle Monnet,Hervé Le Caer,Pierre Fournel,Pauline Linard,David Pérol,Maurice Pérol +16 more
TL;DR: The IFCT–GFPC 0502 study showed a progression-free survival (PFS) benefit with gemcitabine or erlotinib maintenance compared to observation after cisplatin-G induction chemotherapy.
Journal ArticleDOI
OA15.03 Avelumab vs Chemotherapy for First-line Treatment of Advanced PD-L1+ NSCLC: Primary Analysis from JAVELIN Lung 100
Martin Reck,Fabrice Barlesi,J.C. Yang,Virginie Westeel,E. Felip,M. Özgüroĝlu,Manuel Cobo Dols,Rana Sullivan,Dariusz M. Kowalski,Z. Andric,D. Lee,Ahmet Sezer,V S Shamrai,Zsuzsanna Szalai,X. S. Wang,Huanhuan Xiong,Noam Jacob,Keyvan Tadjalli Mehr,K. Park +18 more
TL;DR: Avelumab is an anti-PD-L1 antibody that has shown antitumor activity and an acceptable safety profile in patients with non-small cell lung cancer (NSCLC) as mentioned in this paper .